DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Goldman Sachs - 2 LSEG - 1 ValueAct - 1 Mason Morfit - 1 Lululemon - 1 Sprinklr - 1 Smartsheet - 1 Smucker - 1
Top related locs:
China Midland Rocklin
Top related orgs:
Ultragenyx Pharmaceutical - 2 JPMorgan - 2 LSEG - 1 Revenue - 1 Old Dominion - 1 Fluence Energy - 1 Guggenheim - 1 Walmart - 1

Search resuls for: "osteogenesis"


5 mentions found


☆ Stocks making the biggest moves midday: Five Below, Salesforce, Lululemon, Instacart and more
  + stars: | 2024-06-06 | by ( Sean Conlon | ) www.cnbc.com   time to read: +3 min
For the current quarter, Five Below said it expects between $830 million and $850 million in revenue, while analysts polled by LSEG expected $883 million. The move was made earlier this week and comes just days after the company reported its first revenue miss since 2006. Lululemon issued weak guidance for the current quarter, but its full-year earnings per share guidance was above expectations. The company recorded earnings of $2.66 per share, which is better than the LSEG consensus estimate of $2.33 in earnings per share. The bank cited its earnings per share potential and discounted valuation as reasons for the call.
Persons: LSEG, ValueAct, Mason Morfit, Lululemon, Sprinklr, Smartsheet, Smucker, Goldman Sachs, —, Samantha Subin, Michelle Fox, Lisa Han, Alex Harring Organizations: LSEG, Revenue, Old Dominion, Fluence Energy, Guggenheim, Ultragenyx Pharmaceutical, JPMorgan
☆ Here are Thursday's biggest analyst calls: Apple, Nvidia, Tesla, Netflix, Alphabet, United, JPMorgan, Carvana, Broadcom & more
  + stars: | 2024-06-06 | by ( Michael Bloom | ) www.cnbc.com   time to read: +8 min
Goldman Sachs reiterates Nvidia as buy Goldman said it's sticking with its buy rating on the stock. JPMorgan upgrades StoneCo to overweight from neutral JPMorgan said in its upgrade of the fintech solutions company that it has "appealing" potential for earnings growth. Morgan Stanley reiterates JPMorgan as overweight Morgan Stanley said it's even more bullish on the stock after a meeting with company management. " JPMorgan reiterates Alphabet as overweight JPMorgan said the company is on the "offensive in Gen AI." JPMorgan reiterates Broadcom as overweight The firm said it's sticking with its overweight rating on shares of Broadcom.
Persons: Morgan Stanley, Tesla, Oppenheimer, DA Davidson, Davidson, Goldman Sachs, Goldman, Bernstein, FANG, Redburn, it's bullish, osteogenesis, it's, Robinson, JPMorgan, Disney, Evercore, Moffett, Carvana Organizations: Walmart, Apple, company's, Conference, Nvidia, Energy, Midland shaleco, Endeavor Energy Resources, Airlines, United, Citi, eBay, JPMorgan, BMO, UBS, Mizuho, SEE, P Containers, Deutsche Bank, Deutsche, Google, Jefferies, DFS, Disney, Netflix, CTV, Broadcom Locations: China, Midland, Rocklin
☆ Buy this little-known pharma stock with more than 80% upside ahead, RBC says
  + stars: | 2024-04-22 | by ( Pia Singh | ) www.cnbc.com   time to read: +3 min
Ultragenyx Pharmaceutical has several growth opportunities ahead that could lead its share price to boom over the next year, according to RBC Capital Markets. Analyst Luca Issi initiated research coverage of the pharmaceutical company, which develops treatments for rare and ultra-rare diseases, with an outperform rating and $77 price target. Ultragenyx is forecasting between $500 million and $530 million in revenue for 2024, driven by rare bone disease drug Crysvita, long-chain fatty acid oxidation disorder drug Dojolvi, as well as therapies Mepsevii and Evkeeza. The analyst is also looking ahead to Ultragenyx's treatments for Angelman syndrome, Glycogen storage disease type 1, or GSD1a, plus Wilson's disease as potential opportunities to drive up the stock. Wilson's disease is a rare genetic disorder that prevents the body from eliminating copper, which then leads it to accumulate in the liver, brain and other organs.
Persons: Luca Issi, Issi, Issi's, Issa, GSD1a Organizations: Ultragenyx Pharmaceutical, RBC Capital Markets, U.S . Food, Drug Administration
☆ Opinion: A boast that could sink Trump
  + stars: | 2023-05-21 | by ( Richard Galant | ) edition.cnn.com   time to read: +20 min
We’re looking back at the strongest, smartest opinion takes of the week from CNN and other outlets. CNN —“I’m the one that got rid of Roe v. Wade,” former President Donald Trump boasted Tuesday on Newsmax. Congress has the power to rein in the court, wrote CNN legal analyst and law professor Steve Vladeck, whose new book “The Shadow Docket” focuses on the Supreme Court. Courtesy Boaz FreundIn 2019, then-President Trump issued an executive order requiring hospitals to post the prices of common medical services and procedures. For some, its celebration of a multiracial but purely fictional British aristocracy may even be a big part of its appeal.”As escapism, “Queen Charlotte” is a success.
☆ I'm a leg-lengthening surgeon. I won't do cosmetic procedures because they cheapen what my work is really about — fixing deformities.
  + stars: | 2022-12-29 | by ( Natalie Rahhal | ) www.businessinsider.com   time to read: +11 min
Dr. S. Robert Rozbruch has led limb-lengthening and reconstruction surgery for more than 20 years. Rozbruch performs 350 to 400 limb-lengthening surgeries and deformity corrections a year. I also loved the TV show "M*A*S*H." The character Hawkeye Pierce, who's a surgeon, was like a mentor to me. I really like helping these kinds of patients and feeling their appreciation for something special that not every orthopedic surgeon can do. Cosmetic limb-lengthening surgeries are a one-offI do limb-lengthening reconstruction, not that bullshit cosmetic limb-lengthening that was discussed in GQ.
0 next >>
Total: 5